As with primaquine, tafenoquine can cause severe hemolytic anemia in people with G6PD deficiency. Those with partial deficiency that may be missed by qualitative testing may also be at risk for hemolysis. Plaquenil skin itching Hydroxychloroquine sulfate indications Plaquenil well tolerated Mctd and plaquenil Tafenoquine is an aminoquinoline that is used in combination with other antimalarials for the prevention of relapse of Plasmodium vivax malaria and by itself as prophylaxis against all species of malaria. Tafenoquine has been linked to low rates of transient and asymptomatic serum enzyme elevations during therapy but has not been associated with instances of clinically apparent acute liver injury. Single-dose tafenoquine 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine alone, with a similar safety profile. As a result, it has been selected for further clinical assessment in phase 3. Tafenoquine is an investigational medicine that has completed phase III studies. If approved, it would be the first new medicine for relapsing malaria in over 60 years. Tafenoquine will potentially offer a single-dose cure for the liver-stage of P. vivax infections and will be administered alongside a standard 3-day chloroquine or potentially an ACT treatment regimen. Tafenoquine use in people with G6PD deficiency or unknown G6PD status is contraindicated. Therefore, physicians must perform G6PD testing before prescribing tafenoquine. Act with chloroquine tafenoquine Efficacy and Safety Study of Tafenoquine TQ Co., Tafenoquine plus chloroquine for the treatment and relapse. Plaquenil liver kidney toxicity lymeDoes taking plaquenil cause hair lossHydroxychloroquine interaction with cyclobenzaprinePlaquenil making hair fall out Radical cure” of vivax involves treatment with a drug targeting the dormant liver forms of the parasite given in combination with currently available anti-malarials like chloroquine or artemisinin-based combination therapies ACT. Tafenoquine approved by US FDA for radical cure of vivax.. Tafenoquine - a potential medicine to prevent P. vivax.. Tafenoquine 150 mg tablet Kaiser Permanente. The use of a medicine that targets the dormant liver form of the parasite, co-administered with currently available antimalarials such as chloroquine or artemisinin-based combination therapies ACTs is known as the radical cure. The limited evidence available supports both the use of chloroquine and an ACT for P. ovale and P. malariae. ACT seems to be preferable for optimal treatment of P. knowlesi. ACT is at least equivalent to chloroquine in effectively treating non-falciparum malaria. Tafenoquine, an 8-aminoquinoline drug related to primaquine, is only the second drug of its class to receive FDA approval. Tafenoquine kills both the liver and blood stages of the parasite, broadening its applicability for chemoprophylaxis to all species of malaria.